Biocryst Pharmaceuticals Stock Investor Sentiment
| BCRX Stock | USD 7.99 0.32 3.85% |
Slightly above 52% of BioCryst Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that some traders are interested. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 52
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use BioCryst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward BioCryst Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentAcquiring |
BioCryst Historical Sentiment
Although BioCryst Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding BioCryst, such as negative comments on social media and news outlets, may cause fear in the market and push BioCryst Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of BioCryst.
BioCryst |
BioCryst Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioCryst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioCryst Pharmaceuticals Historical Investor Sentiment
Investor biases related to BioCryst Pharmaceuticals' public news can be used to forecast risks associated with an investment in BioCryst. The trend in average sentiment can be used to explain how an investor holding BioCryst can time the market purely based on public headlines and social activities around BioCryst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioCryst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioCryst Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average BioCryst Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on BioCryst Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about BioCryst Pharmaceuticals that are available to investors today. That information is available publicly through BioCryst media outlets and privately through word of mouth or via BioCryst internal channels. However, regardless of the origin, that massive amount of BioCryst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioCryst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioCryst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioCryst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioCryst Pharmaceuticals alpha.
BioCryst Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | BNP Paribas Financial Markets Has 3.78 Million Stake in BioCryst Pharmaceuticals, Inc. - MarketBeat | 12/05/2024 |
2 | Disposition of 7150 shares by Thackray Helen M. of BioCryst Pharmaceuticals at 7.53 subject to Rule 16b-3 | 12/13/2024 |
3 | Acquisition by Jon Stonehouse of 750250 shares of BioCryst Pharmaceuticals at 7. subject to Rule 16b-3 | 12/19/2024 |
4 | Disposition of 25000 shares by Jon Stonehouse of BioCryst Pharmaceuticals subject to Rule 16b-3 | 12/31/2024 |
5 | BioCryst Pharmaceuticals Inc Projects Strong Revenue Growth and New Drug Developments ... | 01/10/2025 |
6 | BioCryst to Present New ORLADEYO Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma Immunology World Allergy Organization Joint Con... | 02/10/2025 |
7 | BioCryst Pharmaceuticals Q4 2024 Earnings Call Transcript | 02/24/2025 |
8 | Company News for Feb 25, 2025 | 02/25/2025 |
9 | Wall Street Analysts Predict an 84.18 percent Upside in BioCryst Heres What You Should Know | 02/26/2025 |
10 | BioCryst Q4 Earnings How Key Metrics Compare to Wall Street Estimates | 02/27/2025 |
11 | Acquisition by Milano Vincent of 653 shares of BioCryst Pharmaceuticals at 8.61 subject to Rule 16b-3 | 02/28/2025 |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.